ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers. Jing N, Zhang K, Chen X, Liu K, et al. J Clin Invest 2023;133:e168670.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jing N, Zhang K, Chen X, Liu K, et al. ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers. J Clin Invest 2023;133:e168670.
PMID: 38099497